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Background: This randomized, double-blind, multicenter study was designed to evaluate the
efficacy of inhaled once-daily fluticasone furoate (FF) administered in the evening in patients
with persistent asthma not controlled by short-acting beta2 agonists, and to determine the
dose(s) suitable for further development.
Methods: Of 1459 patients screened, 598 received one of six treatments: placebo, FF (25 mg,
50 mg, 100 mg or 200 mg) once daily each evening, or fluticasone propionate (FP) 100 mg twice
daily for 8 weeks. The primary endpoint was change from baseline in pre-dose evening forced
expiratory volume in 1 s (FEV1).
Results: A doseeresponse effect was observed for once-daily FF 25e200 mg including
(p < 0.001) and excluding placebo (pZ 0.03). FF 50e200 mg once daily significantly increased
FEV1 from baseline (p < 0.05 vs placebo), by >200 mL for FF 100 mg and 200 mg. Significant
improvements were also achieved for peak expiratory flow, and percentage symptom-free
and rescue-free 24 h periods. The magnitude of effect was at least as good as twice-daily
FP. Overall, once-daily FF was well tolerated with no systemic corticosteroid effects.f Cape Town Lung Institute, George Street, Mowbray, 7700 Cape Town, South Africa. Tel.: þ27 21 406
.ac.za (E.D. Bateman).
2 Elsevier Ltd. All rights reserved.
Efficacy in asthma of once-daily FF 643Conclusion: FF 50e200 mg/day once daily in the evening demonstrated dose-related efficacy in
asthma with 100e200 mg appearing to be the optimal doses for further evaluation.
ClinicalTrials.gov: NCT00603382.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are the most effective anti-
inflammatory treatments for all severities of persistent
asthma.1e3 Their benefits include control of asthma symp-
toms, improved lung function, and reduced frequency of
exacerbations.4e6 However, these benefits are lost when
treatment is discontinued. Poor adherence is a common
cause of poor asthma control.7
Strategies to improve compliance with controller
therapy include combining treatments such as an ICS and
a long-acting beta2 agonist (LABA) in a single inhaler
8,9 and
less frequent dosing.10 Currently available ICS þ LABA
combinations are licensed for twice-daily dosing, but once-
daily combination regimens are being explored. Once-daily
administration of controller therapy for asthma could offer
greater convenience to the patient, and with this the
potential for improved adherence and asthma control.11
The optimal time for once-daily dosing of an ICS is
unclear. Factors such as night-time worsening of asthma
symptoms and the circadian fluctuation in cortisol levels
support evening dosing.12 Clinical data on this strategy are
limited, but studies with once-daily budesonide, mometa-
sone furoate, and ciclesonide suggest that evening dosing is
at least as effective as morning dosing,13 or may even be
more effective than morning dosing in improving peak
expiratory flow (PEF)12 or forced expiratory volume in 1 s
(FEV1)/forced vital capacity at the same total daily dose of
ICS.14
Demonstrating a dose response to ICS for most efficacy
outcomes in asthma is difficult using conventional study
designs.15 In mild-to-moderate asthma, most benefit with
an ICS is achieved at low doses (equivalent to <100 mg
twice-daily fluticasone propionate [FP])16 and adverse
effects (AEs) increase with increasing doses.17 Results from
preclinical models indicate that fluticasone furoate (FF) is
a novel enhanced-affinity ICS with a pharmacological
profile that demonstrates greater retention in the lung, and
longer duration of action than twice-daily FP.18 FF and FP
have distinct chemical structures and glucocorticoid
receptor binding affinities. FF has an ester derived from
2-furoic acid at the C-17a position replacing the simpler
propionate ester, this results in more complete occupancy
of the 17a pocket in the glucocorticoid receptor.19 This
structural difference with FF results in a higher glucocor-
ticoid receptor binding affinity than with FP.18 Early phase20
and phase IIb21,22 clinical studies support the potential for
FF as a once-daily inhaled asthma control therapy with
a favorable therapeutic index. In addition, FF administered
once daily in the evening is as effective as the same total
daily dose administered twice daily in patients with
asthma, thus supporting the suitability of FF for once-daily
dosing.23 FF is being co-developed with vilanteroltrifenatate (VI, GW642444M), a new LABA with inherent
24 h activity,24 in a novel dry powder inhaler (nDPI)
formulation.
We evaluated the efficacy and safety of four doses of FF
administered once daily in the evening in patients with
persistent, uncontrolled asthma in a placebo-controlled
study with FP as active control. The study was powered to
demonstrate a doseeresponse effect on lung function
(FEV1). Preliminary results from this study have been
previously presented as an abstract.25
Patients and methods
Patients
Patients were aged 12 years with a diagnosis of persistent
asthma not optimally controlled on short-acting beta2
agonists (SABA) or other non-steroidal controllers, which
they had been using for 3 months, and a baseline FEV1 of
40%e90% of predicted normal between 17.00 h and 23.00 h
(or 40%e85% between 05.00 h and 12.00 h to account for
the known diurnal lung function variation in asthma
patients). Patients had to demonstrate reversibility of FEV1
of at least 12% and 200 mL with salbutamol inhalation
aerosol.
After 4 weeks’ run-in, patients entered the treatment
period if evening pre-dose FEV1 was 40%e90% and they
continued to be symptomatic (combined daily asthma
symptom score1 or salbutamol use on4 of the last 7 days
of run-in). Key exclusion criteria at enrollment and at the
end of the run-in period are detailed in Supplement 1.
Study design and treatments
This was a randomized, double-blind, double-dummy,
parallel-group, placebo- and active-controlled study (GSK
study FFA109687; ClinicalTrials.gov NCT00603382) con-
ducted in 142 centers in 14 countries worldwide, between
19 December 2007 and 2 October 2008 (for details see
Supplementary Table 1). The study was approved by local
ethics committees, and conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines. Written informed consent was obtained from each
patient.
Patients who successfully completed run-in were
randomized (ratio, 1:1:1:1:1:1) to one of six treatment
groups: placebo, FF (25 mg, 50 mg, 100 mg, or 200 mg) once
daily in the evening, or FP 100 mg twice daily (an active
control for assay sensitivity and assessment of the relative
magnitude of responses to FF). Patients and investigators
were blinded to treatment assignment and the placebo and
FF formulations were indistinguishable. Further details of
644 E.D. Bateman et al.the study design, randomization schedule (RandAII) and
allocation method (RAMOS) are described in Supplement 2.
Treatment duration was 8 weeks. FF was administered
once daily in the evening using a nDPI, further details of
which will be described in a separate publication. FP was
administered twice daily via Diskus/Accuhaler. Placebo
was administered twice daily via Diskus/Accuhaler for each
FF group, every evening via the nDPI device for the FP
group, and via both delivery systems for the placebo group.
Assessment of appropriate device use was made at each
study visit and adherence was assessed using the device
dose counters. Other than as-needed salbutamol, no
concomitant asthma medications were permitted during
the treatment period. All other permitted medications
(Supplement 1) taken were recorded.
Study visits took place at Weeks 1, 2, 4, 6, and 8 of
active treatment; a follow-up clinic visit or telephonic
consultation was conducted 1 week after completing study
medication.Efficacy measurements
Using the eDiary (Asthma Monitor II [AM II] electronic diary
device, Cardinal Health Research Services, Hoechberg,
Germany)26e28 and with time and date stamped, patients
kept a daily record of daytime and night-time asthma
symptom scores for each 24 h period (daytime symptoms
scored from ‘0, no symptoms’, to ‘5, symptoms so severe
that patient could not go to work or perform normal daily
activities’; night-time symptoms scored from ‘0: no symp-
toms’, to ‘4: symptoms so severe that the patient did not
sleep at all’), rescue salbutamol use, and morning and
evening PEF measurements (pre-dose and pre-rescue bron-
chodilator). FEV1 was measured before dosing with study
medication at evening clinics using centralized spirometry
(MasterScope CT) and according to ATS/ERS guidelines.29
The primary endpoint was mean change from baseline in
pre-dose evening FEV1 at the end of 8 weeks’ treatment
(with and without placebo adjustment). Secondary
endpoints were mean changes from baseline in daily
evening and daily morning PEF averaged over the 8-week
treatment period; percentage of symptom-free 24 h
periods during treatment; percentage of rescue-free 24 h
periods; and number of withdrawals due to lack of efficacy
(worsening of asthma) during treatment. Other efficacy
endpoints evaluated but not reported here are shown in
Supplement 3.Safety evaluation
AEs were coded using the MedDRA dictionary (Version 11)
and reported by primary System Organ Class and Preferred
Term. Standard laboratory parameters (hematology, clin-
ical chemistry, and urinalysis) and 24 h urinary cortisol (UC)
excretion assessment were performed before and at the
end of treatment and were analyzed at a central labora-
tory. Vital signs and oropharyngeal examination (for signs of
oropharyngeal candidiasis; coded as oral candidiasis,
oropharyngeal candidiasis, or candidiasis) were assessed at
screening and at Visits 3e8.Pharmacokinetic assessments
Blood samples for pharmacokinetic assessment of once-
daily FF were collected from all patients before and after
dosing at Weeks 2 and 8 of study treatment and analyzed at
a central laboratory using validated methods, with a lower
limit of quantification of 10 pg/mL.
Statistical analyses
A total of 594 evaluable patients were required to
demonstrate a 200 mL improvement per 200 mg of FF
(doseeresponse slope 1 mL/mg) in the primary endpoint,
with 96% power and significance at the two-sided 5% level.
The study had 90% power to detect a 200 mL difference in
pair-wise comparisons between any active dose and
placebo.
The intent-to-treat (ITT) population included all
patients randomized to treatment and who received at
least one dose of study medication, and constituted the
primary population for all analyses of efficacy and safety
measures (excluding UC analyses). The per protocol (PP)
population included ITT population patients without a full
protocol deviation and was used for confirmatory analyses
of the primary efficacy endpoint. The UC population
comprised patients whose urine samples did not have con-
founding factors that could affect the interpretation of
results.
The primary treatment comparison was for linear dosee
response in pre-dose evening FEV1 at Week 8 across the four
FF doses (with and without placebo) to demonstrate overall
efficacy of FF. Each dose of FF was also compared with
placebo to identify effective doses, using analysis of
covariance (ANCOVA) with last observation carried forward
to impute missing data. Pair-wise comparisons were per-
formed for the other key efficacy endpoints on the ITT
population, and for 24 h UC excretion on the ITT and UC
populations.Results
Study population
Of 1459 patients recruited, 598 were randomized and
received at least one dose of study treatment (ITT pop-
ulation; Fig. 1). Demographics and baseline characteristics
were similar across groups (Table 1). Mean age was 37e41
years; over half of patients had at least a 10-year history of
asthma, and approximately 20% had an asthma exacerba-
tion during the last 6 months. The most frequently taken
asthma medications taken during the run-in period were
salbutamol (90%e96%) and montelukast (5%)
(Supplementary Table 2). A total of 518 patients completed
study treatment. Reasons for withdrawal are detailed in
Supplementary Fig. 1.
Adherence to study medication was consistently high
(92.4%e97.0% for the Diskus/Accuhaler; 96.0%e101.0% for
the nDPI). Mean exposure to study medication was similar
across the active treatment groups (51.0e54.1 days for
both devices) and placebo (49.9/49.8 days).
Figure 1 Patient disposition.
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A significant doseeresponse relationship for change in pre-
dose evening FEV1 (baselineeWeek 8) was achieved across
once-daily FF (25e200 mg) both when placebo was included
(p < 0.001) and when placebo was not included (pZ 0.03;
Table 2). At Week 8, all active treatment groups showed
a >200 mL improvement in pre-dose FEV1 from baseline;
the 100 mg and 200 mg once daily doses achieved a >200 mL
difference compared with placebo (p < 0.001). FF 50 mg
once daily, although failing to reach the pre-defined 200 mL
difference, was also significantly better than placebo
(p < 0.05), but superiority vs placebo was not demon-
strated for FF 25 mg once-daily or for FP 100 mg twice-daily
(Fig. 2). Similar results were shown in the PP population,
except that FF 25 mg once-daily also achieved significance
(data not shown).
In the secondary endpoint analyses, evening PEF
improvements from baseline were largest in the FF 50 mg
and 200 mg once-daily groups (mean difference 20.7 and
21.7 L/min, respectively, vs placebo; p < 0.001). Signifi-
cant but smaller differences were also achieved with FF
25 mg once daily (14.0 L/min, p Z 0.019) and 100 mg once
daily (16.1 L/min, p Z 0.005) and were of a similar
magnitude to FP 100 mg twice daily (14.9 L/min;
pZ 0.011). Similarly, all active treatment groups improvedmorning PEF relative to baseline (Fig. 3) and these changes
were significantly greater than with placebo; FF 200 mg
once daily exhibited the greatest difference (22.0 L/min;
p < 0.001).
Trends in the percentage of 24 h periods that were
symptom-free or rescue-free are shown in Figs. 4 and 5,
respectively. For symptom-free periods, FF 100 mg once
daily demonstrated the greatest increase from baseline
relative to placebo (20.2%). FF 50 mg and 200 mg once daily
showed numerically lower increases, similar in magnitude
to the FP 100 mg twice-daily group. For all except the FF
25 mg once-daily group, the effect was significantly better
than for placebo. A similar pattern was evident for rescue-
free periods.
Withdrawal rates due to lack of efficacy were highest in
the placebo and FP twice-daily groups (15% and 11%,
respectively; Fig. 1). Rates for FF once-daily ranged from
3% to 9%, and for the 50 mg (3%) and 100 mg (5%) once-daily
groups were significantly lower than for placebo (pZ 0.004
and p Z 0.032, respectively).Safety
Overall, 26%, 34%, and 20%e32% of patients in the placebo,
FP twice-daily and FF once-daily groups, respectively,
Table 2 Linear trend test and statistical analysis of change from baseline in pre-dose (trough) FEV1 at Week 8 (ITT
population).
Placebo FF FP
25 mg OD 50 mg OD 100 mg OD 200 mg OD 100 mg BD
Patients, n 93 94 97 109 94 101
Trough FEV1 (L)
LS mean (Week 8) 2.515 2.617 2.644 2.719 2.745 2.621
LS mean change from
baseline (Week 0)
0.137 0.239 0.266 0.341 0.367 0.243
Difference vs placebo
LS difference 0.101 0.129 0.204 0.230 0.106
95% CI 0.018, 0.221 0.011, 0.247 0.089, 0.319 0.111, 0.349 0.010, 0.223
p value (vs placebo) e 0.095 0.033 <0.001 <0.001 0.074
Linear trend, FF and placebo (excluding placebo)
p value <0.001 0.030
Slope (mL/mg) 1.016 0.711
95% CI (0.472, 1.559) (0.069, 1.354)
BD: twice daily; CI: confidence interval; FEV1: forced expiratory volume in 1 s; FF: fluticasone furoate; FP: fluticasone propionate; LS:
least squares; OD: once daily.
Table 1 Demographics and baseline characteristics (ITT population).
Placebo Fluticasone furoate FP
25 mg OD 50 mg OD 100 mg OD 200 mg OD 100 mg BD
Patients, n 94 97 100 110 95 102
Age years, mean (range) 39.2 (12e78) 37.7 (13e69) 38.3 (12e65) 36.8 (12e70) 40.7 (12e72) 39.9 (12e74)
Females, n (%) 47 (50) 57 (59) 59 (59) 60 (55) 60 (63) 56 (55)
Race, n (%)
White 69 (73) 64 (66) 72 (72) 76 (69) 64 (67) 74 (73)
African American/African 5 (5) 4 (4) 4 (4) 8 (7) 6 (6) 5 (5)
Asian 7 (7) 13 (13) 9 (9) 10 (9) 10 (11) 10 (10)
Other/mixed race 13 (14) 16 (16) 15 (15) 16 (15) 15 (16) 13 (13)
Duration of asthma, n (%)
<6 months to <5 years 16 (17) 19 (20) 20 (20) 26 (24) 22 (23) 19 (19)
5 years to <10 years 13 (14) 20 (21) 15 (15) 19 (17) 22 (23) 16 (16)
10 years 65 (69) 58 (60) 65 (65) 65 (59) 51 (54) 67 (66)
History of atopy, n (%) 45 (48) 38 (39) 50 (50) 47 (43) 34 (36) 39 (38)
Exacerbations (1) in
previous 6 months, n (%)
20 (21) 17 (18) 19 (19) 18 (16) 24 (25) 17 (17)
Lung function
FEV1 at screening, mean
Pre-bronchodilator (L) 2.320 2.394 2.335 2.279 2.163 2.238
Pre-bronchodilator
(% predicted)
67.03 69.69 69.20 67.16 66.56 67.35
Reversibility (%) 28.09 26.43 29.84 31.60 29.32 29.05
FEV1 at baseline
a, mean (L) 2.373 2.456 2.427 2.419 2.210 2.343
Daily diary data at baselinea, mean
PM PEF (L) 355.4 370.8 364.5 372.9 337.3 347.2
AM PEF (L) 342.7 359.0 356.3 362.2 326.0 337.2
Rescue-free 24 h periods (%) 10.5 9.5 13.1 15.4 9.0 9.8
Symptom-free 24 h
periods (%)
13.5 11.0 9.5 14.2 8.3 9.2
BD: twice daily; FEV1: forced expiratory volume in 1 s; FP: fluticasone propionate; OD: once daily; PEF: peak expiratory flow.
a Baseline defined as start of randomization period (Visit 3).
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Figure 2 Adjusted treatment differences of change from
baseline in trough FEV1 (last observation carried forward) at
Week 8 (ITT population). Values are expressed in mL. BD: twice
daily; CI: confidence interval; FF: fluticasone furoate; FP: flu-
ticasone propionate; OD: once daily.
Figure 4 Change from baseline in symptom-free 24 h periods
(ITT population). Values are based on summary statistics. BD:
twice daily; FF: fluticasone furoate; FP: fluticasone propio-
nate; OD: once daily.
Efficacy in asthma of once-daily FF 647reported at least one on-treatment AE (Table 3). AEs
considered drug-related were low in all groups (FF 25 mg,
0%; to FP, 6%), with no apparent dose-dependent events.
Six serious AEs occurred in four patients; none were
considered to be study medication related: snake bite (FF
25 mg; patient discontinued study treatment); depression
(FF 100 mg); gastritis (FP); and chest pain, hyperhidrosis and
hypertension (FP; discontinued study). Five further with-
drawals were linked with (non-serious) AEs: FF 50 mg
(nZ 1), FF 100 mg (nZ 2), FF 200 mg (nZ 1) once daily and
FP 100 mg twice daily (n Z 1). There were no deaths or
hospitalizations associated with AEs.
Asthma exacerbations (defined as worsening asthma
requiring any treatment other than study medication or
rescue salbutamol alone) occurred in seven patients and
necessitated study withdrawal: FF 25 mg (nZ 1), FF 100 mg
(nZ 3), FF 200 mg (nZ 1) and FP (nZ 2). Three patients in
the FF 100 mg once-daily group and two patients in the FP
100 mg twice-daily group required oral corticosteroids but
none required hospitalization. The primary cause of most
exacerbations was an upper respiratory tract infection and
two patients (FF 200 mg; FP) cited lack of efficacy. The
incidence of on-treatment oropharyngeal candidiasis was
low across all groups: FF 25 mg, 0%; FF 50e200 mg, 2%e4%;
FP, <1%; and placebo, 0%.Figure 3 Mean change from baseline in daily morning PEF
(ITT population). BD: twice daily; FF: fluticasone furoate; FP:
fluticasone propionate; OD: once daily; PEF: peak expiratory
flow.A small proportion of patients (2%e3%) had a shift from
their baseline UC levels to ‘low’, 7%e16% had a shift to
‘high’, and 79%e88% had ‘no change/normal’ over the
treatment period (ITT population). There were no statis-
tically significant differences in UC excretion between
placebo and any of the FF groups or FP in the UC pop-
ulation (ratio to placebo, 0.94e1.17; Fig. 6 and
Supplementary Fig. 2). No clinically important changes
were noted among laboratory parameters or vital sign
assessments.Pharmacokinetic analysis
Of 1456 evaluable samples in 381 patients (94.8% of the FF
ITT population), 71.0% were below the lower limit of
quantification (10 pg/mL) for FF. The number of patients
reporting at least one measurable value increased with
dose level; however, the low number of quantifiable results
did not permit a formal pharmacokinetic analysis, but
confirmed low systemic exposure.Figure 5 Change from baseline in rescue-free 24 h periods
(ITT population). Values are based on summary statistics. BD:
twice daily; FF: fluticasone furoate; FP: fluticasone propio-
nate; OD: once daily.
Table 3 Summary of adverse events and most common on-treatment adverse events (3% in any treatment group), (ITT
population).
Placebo FF FP
25 mg OD 50 mg OD 100 mg OD 200 mg OD 100 mg BD
Patients, n 94 97 100 110 95 102
Patients with any on-treatment AE, n (%) 24 (26) 19 (20) 28 (28) 35 (32) 27 (28) 35 (34)
Patients with drug-related AE, n (%) 2 (2) 0 3 (3) 7 (6) 4 (4) 6 (6)
Patients with on-treatment serious AEs, n (%) 0 1 (1) 0 1 (<1) 0 2 (2)
Patients with AEs leading to withdrawal, n (%) 0 1 (1) 1 (1) 2 (2) 1 (1) 2 (2)
Most common on-treatment AEs
Headache 10 (11) 6 (6) 6 (6) 12 (11) 5 (5) 12 (12)
Oropharyngeal pain 1 (1) 0 1 (1) 4 (4) 3 (3) 2 (2)
Nasopharyngitis 1 (1) 0 0 4 (4) 3 (3) 2 (2)
Sinusitis 1 (1) 2 (2) 0 0 2 (2) 3 (3)
Upper respiratory tract infection 0 2 (2) 1 (1) 3 (3) 0 1 (<1)
Insomnia 1 (1) 0 1 (1) 3 (3) 0 1 (<1)
Back pain 0 0 3 (3) 0 1 (1) 1 (<1)
AE: adverse event; BD: twice daily; FF: fluticasone furoate; FP: fluticasone propionate; OD: once daily.
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The results of this study show that 8 weeks’ treatment with
FF at doses ranging from 25 to 200 mg, administered once
daily in the evening, provided significant, dose-dependent
improvements in the primary endpoint of pre-dose
(trough) evening FEV1, including significant improvements
over placebo at dose levels of 50 mg and greater. This,
together with improvements in secondary endpoints and its
favorable safety profile, support the benefit that this new
ICS can offer to patients with asthma.
This study, in a large patient cohort, was designed to
include patients who required a step-up to Step 2 of asthma
treatment guidelines,1,3 i.e. with asthma not controlled on
as-needed SABA alone; patients with an asthma exacerba-
tion within 3 months of visit 1 were excluded as this study
sought to identify the lowest potential dose of FF for step-
up therapy. The principal comparison was once-daily FF vs
placebo. FP 100 mg twice daily, a standard low-dose ICS at
Step 2, was included as an active control to permit an
assessment of assay sensitivity and comparison with once-
daily FF responses. This study was not powered for
a formal comparison between FF and FP but rather soughtFigure 6 Adjusted treatment ratios for 24 h urinary cortisol
excretion (urinary cortisol population; n Z 425). BD: twice
daily; CI: confidence interval; FF: fluticasone furoate; FP: flu-
ticasone propionate; OD: once daily.to evaluate whether a dose response in change from
baseline lung function can be demonstrated with once-daily
FF. For this reason, we selected as the primary endpoint
pre-dose (trough) evening FEV1, which meant FEV1 was
measured 24 h after the last dose of FF and 12 h after the
last dose of FP. While the magnitude of effect with all once-
daily FF doses >50 mg was numerically higher than that
achieved with twice-daily FP, FP did not demonstrate
superiority to placebo in FEV1 change from baseline over
the 8 weeks of the study. This differed from findings in
studies identical in design to this one conducted in patients
with more severe asthma uncontrolled by low or moderate-
dose ICS where FP dosed at 250 mg21 or 500 mg22 twice daily
significantly improved lung function. Of note in those
studies, the placebo response was 65 mL21 and 43 mL22
compared with the þ137 mL observed in this study. In
a previous 12-week study of FP dosed at 100 mg or 200 mg in
ICS-naı¨ve asthma patients FEV1 was improved by 270 mL
and 110 mL, respectively, compared with an 80 mL decline
in the placebo group.30,31 These findings suggest that the
lack of efficacy observed with FP 100 mg twice-daily in this
study resulted from the high placebo response, rather than
a lack of efficacy with FP per se. There are a number of
possible explanations for the high placebo response. First,
it is possible that inclusion into a clinical trial resulted in all
patients increasing their use of rescue therapy, which was
maintained in the placebo group, but as shown, was
significantly reduced by active treatment (Fig. 5). Secondly,
the significantly higher withdrawal rate in the placebo
group, relative to active treatment, will have resulted in
a ‘healthy survivor’ effect, resulting in a subset of patients
in the placebo group with better lung function contributing
more data to the final analysis than those withdrawn due to
poorer lung function. Finally, FEV1 was measured at the
trough of FF dosing in the evening and it is possible that the
natural diurnal variation seen in asthma lung function may
have contributed to higher than expected FEV1 measure-
ments. Over 8 weeks, significant improvements in evening
PEF were observed, despite the variability of the data. It is
conceivable that the increase in PEF observed in the
Efficacy in asthma of once-daily FF 649placebo group toward the end of the study period (Fig. 3)
was also consequent to the ‘healthy survivor’ effect.
We did not compare once-daily with twice-daily dosing
of FF in our study. However, another study of FF in asthma
did and showed non-inferiority of once-daily FF adminis-
tered in the evening (200 mg) compared with FF adminis-
tered twice daily (100 mg, morning and evening),23 thereby
supporting suitability of FF for once-daily dosing. A goal of
this study was to determine the optimal once-daily dose of
FF. In the past, demonstrating a doseeresponse relation-
ship for ICS in patients with mild-to-moderate asthma
has proved difficult because of the relatively flat
doseeresponse curve for FEV1 and other endpoints used to
measure efficacy. Furthermore, most of the benefit of an
ICS treatment is observed at doses equivalent to <100 mg of
FP twice daily.16 An important factor that contributed to
the success of this study was the exclusion of patients who
had recently used or were currently using ICS. Another
important factor was the selection of FF doses. Based on
the efficacy and safety profiles demonstrated in earlier
clinical studies [GSK data on file], it was anticipated that
the 100 and 200 mg doses would be the most effective
doses. The lowest dose (25 mg) was expected to have
minimal if any efficacy, but permitted a more thorough
evaluation of the doseeresponse effects of FF. Overall, FF
was well tolerated, and there was no evidence of dose-
related AEs. A lack of systemic effect with once-daily FF
was supported by the absence of reduced 24 h UC, a result
consistent with low levels of FF detected in pharmacoki-
netic samples. Although a small number of asthma exac-
erbations were reported, this outcome cannot be
adequately assessed in an 8-week study. Furthermore, the
protocol defined that patients were withdrawn at the first
signs of worsening asthma. Limitations of the study
included the high placebo response, which may have been
influenced by the strict withdrawal criteria that excluded
patients who were deteriorating.
The need for improved interventions for patients with
uncontrolled asthma is highlighted by the huge economic
burden associated with this patient population. A cost-of-
illness study in Italy found that half of the total economic
burden was due to a limited proportion of poorly controlled
patients.32 Current efforts to address this burden focus not
only on development of new drugs, but also on strategies to
improve adherence to controller therapy and to optimize
efficacy/safety ratios through better understanding of
doseeresponse relationships, and finally dosing strategies
such as once-daily dosing.
There is evidence that evening dosing with ICS could
achieve better asthma control than morning dosing.12,14,33
Yet, despite the known diurnal variation in asthma, few
studies have directly compared morning vs evening dosing
of ICS. Evening dosing with mometasone furoate DPI was
superior to morning dosing in a double-blind, randomized,
placebo-controlled study in patients previously on regular
ICS.14 However, another double-blind, randomized study
concluded that morning and evening dosing of ciclesonide
were equally effective, with the exception of morning PEF
which was higher with evening dosing.12 Similarly, in
another study with FF, evening dosing of once-daily FF was
as effective (measured as change from baseline in trough
FEV1) as once-daily dosing in the morning.
34In conclusion, FF administered once daily in the evening
led to dose-related efficacy at doses of 50e200 mg/day and
was well tolerated in asthma patients symptomatic on non-
steroidal asthma therapy. FF 100e200 mg produced the
greatest improvement in efficacy, without evidence of
safety or tolerability concerns, and supports further eval-
uation as a monotherapy and in combination with a LABA in
patients whose disease severity requires treatment with
ICS/LABA.
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